During this period, the TGF-β inhibitor, EW-7197 could not reduce primary cancer burden in alone treatment and the combinatorial EW-7197 treatment could not enhance the cytotoxic effect of paclitaxel (Figure 2B). The gene discussed is TGFB1; the disease is cancer.